JP7297930B2 - クローン病を治療する方法に使用するためのミリキズマブ - Google Patents

クローン病を治療する方法に使用するためのミリキズマブ Download PDF

Info

Publication number
JP7297930B2
JP7297930B2 JP2021562882A JP2021562882A JP7297930B2 JP 7297930 B2 JP7297930 B2 JP 7297930B2 JP 2021562882 A JP2021562882 A JP 2021562882A JP 2021562882 A JP2021562882 A JP 2021562882A JP 7297930 B2 JP7297930 B2 JP 7297930B2
Authority
JP
Japan
Prior art keywords
milikizumab
weeks
administered
dose
endoscopic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530397A (ja
Inventor
ウィリアム フリードリック，スチュアート
フレデリック ポラック，ポール
ローレンス タットル，ジェイ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2022530397A publication Critical patent/JP2022530397A/ja
Priority to JP2023097427A priority Critical patent/JP7761614B2/ja
Application granted granted Critical
Publication of JP7297930B2 publication Critical patent/JP7297930B2/ja
Priority to JP2025116307A priority patent/JP2025148449A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
JP2021562882A 2019-04-22 2020-04-15 クローン病を治療する方法に使用するためのミリキズマブ Active JP7297930B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023097427A JP7761614B2 (ja) 2019-04-22 2023-06-14 クローン病を治療する方法に使用するためのミリキズマブ
JP2025116307A JP2025148449A (ja) 2019-04-22 2025-07-10 クローン病を治療する方法に使用するためのミリキズマブ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
US62/836,910 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097427A Division JP7761614B2 (ja) 2019-04-22 2023-06-14 クローン病を治療する方法に使用するためのミリキズマブ

Publications (2)

Publication Number Publication Date
JP2022530397A JP2022530397A (ja) 2022-06-29
JP7297930B2 true JP7297930B2 (ja) 2023-06-26

Family

ID=70554215

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021562882A Active JP7297930B2 (ja) 2019-04-22 2020-04-15 クローン病を治療する方法に使用するためのミリキズマブ
JP2023097427A Active JP7761614B2 (ja) 2019-04-22 2023-06-14 クローン病を治療する方法に使用するためのミリキズマブ
JP2025116307A Pending JP2025148449A (ja) 2019-04-22 2025-07-10 クローン病を治療する方法に使用するためのミリキズマブ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023097427A Active JP7761614B2 (ja) 2019-04-22 2023-06-14 クローン病を治療する方法に使用するためのミリキズマブ
JP2025116307A Pending JP2025148449A (ja) 2019-04-22 2025-07-10 クローン病を治療する方法に使用するためのミリキズマブ

Country Status (17)

Country Link
US (1) US20220040299A1 (enExample)
EP (1) EP3958897A1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
CA (1) CA3134587A1 (enExample)
EA (1) EA202192532A1 (enExample)
IL (2) IL286818B1 (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527380A (ja) 2015-09-18 2018-09-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
EP3693007A1 (en) 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
AU2017312049A1 (en) * 2016-08-19 2019-02-21 Janssen Biotech, Inc. Methods of treating Crohn's Disease with an anti-NKG2D antibody
KR20200037258A (ko) * 2017-07-10 2020-04-08 람밤 메드-테크 엘티디. 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527380A (ja) 2015-09-18 2018-09-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Expert Opinion on Investigational Drugs，2018年，Vol.27, No.8, pp.649-660

Also Published As

Publication number Publication date
CN119700968A (zh) 2025-03-28
JP2022530397A (ja) 2022-06-29
JP7761614B2 (ja) 2025-10-28
AU2020263238C1 (en) 2024-02-22
KR20210142704A (ko) 2021-11-25
AU2023265759A1 (en) 2023-12-07
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
BR112021018930A2 (pt) 2022-01-18
CA3134587A1 (en) 2020-10-29
UA128657C2 (uk) 2024-09-18
IL324048A (en) 2025-12-01
CN113677366A (zh) 2021-11-19
EP3958897A1 (en) 2022-03-02
WO2020219314A1 (en) 2020-10-29
EA202192532A1 (ru) 2022-01-21
AU2020263238A1 (en) 2021-11-04
ZA202108094B (en) 2025-05-28
NZ781127A (en) 2025-06-27
IL286818A (en) 2021-10-31
AU2020263238B2 (en) 2023-08-17
SG11202110619XA (en) 2021-11-29
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
IL286818B1 (en) 2025-11-01
JP2025148449A (ja) 2025-10-07
MX2021012848A (es) 2021-12-10
KR102869852B1 (ko) 2025-10-14
KR20250153865A (ko) 2025-10-27
TW202515610A (zh) 2025-04-16
MA55756A (fr) 2022-03-02

Similar Documents

Publication Publication Date Title
US20250034243A1 (en) Methods of treating ulcerative colitis
JP2025176106A (ja) Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
Armuzzi et al. Ustekinumab in the management of Crohn’s disease: Expert opinion
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
EA049081B1 (ru) Способы лечения язвенного колита

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230614

R150 Certificate of patent or registration of utility model

Ref document number: 7297930

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150